Kairos Pharma, LTD. (KAPA) stock
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)
Close on Nov 17, 2026Market cap $1.49MP/E –Yield –
Kairos Pharma EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Kairos Pharma
Kairos Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?